In August 2008, Valeant and GlaxoSmithKline (GSK) entered into an exclusive worldwide collaboration agreement for ezogabine/retigabine, a Phase III, first-in-class neuronal potassium channel opener for the adjunctive treatment of partial-onset seizures in adult patients with refractory epilepsy. Valeant and GSK filed a New Drug Application in the U.S. and a Marketing Authorization Application in Europe in 2009. The FDA action date is November 30, 2010.
Approved by the FDA in August 2008, Xenazine® is indicated for the treatment of chorea associated with Huntington's disease (HD). Xenazine® is marketed to U.S. specialist physicians through the sales force of Ovation Pharmaceuticals, Inc. (acquired by H. Lundbeck A/S in March 2009). Pursuant to a supply-and-distribution agreement, Biovail supplies Xenazine® tablets to Ovation for a variable percentage of the product's annual net sales, and pays a royalty to a third party that was acquired by H. Lundbeck A/S in July 2009.
In November 2010, Valeant and Kadmon Pharmaceuticals LLC concluded two strategic agreements for the development and commercialization of taribavirin and the commercial marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV).